Board of Directors

//Board of Directors
Board of Directors 2019-07-25T15:03:11+00:00
Kevin Rakin

Mr. Rakin has been an Oramed Director since 2016.

He is a Co-founder and Partner at HighCape Partners, a growth equity life sciences fund.

Previously, Mr. Rakin was the President of Regenerative Medicine at Shire plc, and served as the Chairman and Chief Executive Officer of Advanced BioHealing, Inc. from 2007 until its acquisition by Shire for $750 million in June 2011.

David Slager

Mr. Slager has been an Oramed Director since 2016.

He is the Founder and Chairman of Regals Capital, and the Portfolio Manager of the Fund.

Prior to founding Regals Capital, Mr. Slager was the Chairman and the Portfolio Manager of Attara Capital, and the Vice Chairman of Atticus Capital LP.

He was also part of the Proprietary Equity Arbitrage Group at Goldman, Sachs & Co. in London and a financial analyst at Goldman, Sachs & Co. in New York and London.

Leonard Sank

Mr. Sank has been an Oramed director since 2007.

He is an entrepreneur and businessman, based in South Africa, who is devoted to entrepreneurial endeavors and initiatives.

Mr. Sank has over 20 years of experience in important leadership roles in building and developing businesses and he serves on the Board of Directors of several other companies in a variety of sectors.

Aviad Friedman

Mr. Friedman has been an Oramed Director since 2016.

Mr. Friedman is Chief Executive Officer of Most Properties 1998 Ltd. and the Chairman of the Israel Association of Community Centers.

Mr. Friedman was the first Director General of Israel’s Ministry of Diaspora Affairs and served as personal advisor to Prime Minister Ariel Sharon.

He also served as Chief Operating Officer of one of Israel’s premier newspapers, Ma’ariv and has more than 14 years of experience serving on boards of public and private companies including Maayan Ventures, Capital Point and Rosetta Green Ltd.

Xiaoming Gao

Mr. Gao has been an Oramed director since 2019.

Mr. Gao has more than 30 years of experience in the insulin industry and was responsible for introducing Novo Nordisk insulin to China.

In 2005, he invested and established Hefei Life Science and Technology Park Investment and Development Co., LTD.,  and led the existing team to successfully complete the registration of imported Insulin-SciLin in China.

In 2007, he founded Hefei Tianmai Biotechnology development Co., Ltd. (“HTBT”) and started recombinant human insulin and insulin analogs’ R&D manufacturing for the Greater China region, which is commercially available under the CFDA in China.

Nadav Kidron, Esq
Chief Executive Officer, President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He is a member on the Board of Directors of Entera Bio, which started as a joint venture formed by Oramed and DNA Biomedical Solutions; and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelors degree in law and an international masters in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

Miriam Kidron, Ph.D
Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.